Scinai regains full compliance with nasdaq listing requirements

Jerusalem , aug. 29, 2024 /prnewswire/ -- scinai immunotherapeutics ltd. (nasdaq: scni) ("scinai", or the "company"), a biopharmaceutical company focused on developing inflammation and immunology (i&i) biological products and on providing cdmo services through its scinai bioservices business unit, today announced that on august 27, 2024, it received formal notification (the "notification") from the listing qualification department (the "staff") of the nasdaq stock market ("nasdaq") that the company has regained compliance with nasdaq listing rule 5550(b)(1) (the "rule") that requires listed companies to maintain stockholders' equity of at least $2.5 million.
NDAQ Ratings Summary
NDAQ Quant Ranking